




The Overlooked Epidemic
Pneumonia
in children
20-50%
due to Mycoplasma
Infection – CDC

M Bio Technology Inc.

More than cold and cough



**CNS (ADEM / MS)
& Mental Disease**

5% - 50% pneumonia and autoimmune
diseases can be attributed to Mycoplasma

Kazuhiro Matsuda matsuda-k@mbiotech.org +81(90) 8486-5727 <https://en.mbiotechnology.com/>

Targeting Infection-Triggered Autoimmune Diseases: AI Diagnostics × Preventive Vaccines × Global Trials

Founded in 2005, M Bio Technology is focused on the drug discovery and development of breakthrough therapeutic strategy for autoimmune diseases caused by infection, proposing vaccine, antibody drug, and AI digital program, based on world-leading platform technology.

Stage: Seed, Pre-Series A, Series A

Industry: Drug Discovery Startup

Number of employees: 5

Market size: \$20 B

**Investment opportunity: Seed: \$1M /
Pre-Series A: \$3M / Series A: \$10M**

Use of funds:

- FDA submission and consulting
- GLP/GMP manufacturing
- Strategic pharma alliances projected to drive \$2B+ enterprise value by 2030.

MANAGEMENT TEAM



Kazuhiro Matsuda, MD, PhD
Founder & CEO
Chairman of Scientific
Advisory Boards
Immunology, Microbiology
and Internal medicine



Sachie Matsuda, MD, PhD
Founder & CEO
Clinical Development
Dermatologist

CURRENT STATUS

- BDD/BTD application in preparation
: Efficacy and safety data of non-GLP vaccines have been obtained
- Collaboration with global multicenter physician-led clinical investigators

CHALLENGE


- Autoimmune diseases triggered by infections are often misdiagnosed.
- Current diagnostics fail to detect microbial triggers.
- The essence of the problem was diagnostic method and medical guidelines.

SOLUTION

Mycoplasma glycolipid-antigen

Integrated platform: diagnostics + therapeutics + digital support

1. MID Prism– AI diagnostic system for microbial triggers
2. MID Modality– Therapeutics for infection-linked autoimmune conditions
3. MID Navigator – Digital platform for patient and physician support



MARKET

- Therapeutic: Encephalitis/ADEM/MS – Orphan Disorders
- Preventive: Vaccine strategy interstitial pneumonia

MILESTONES

Clinical Development Timeline (ADEM/MS - Orphan Disorders)		2025	2026	2027	2028	2029	2030	2031
Regulatory consultations (PMDA/FDA)	•Targets: MID Prism (AI diagnostic) and MID Modality (therapeutic platform) •BDD/BTD acquisition •Orphan designation •Fast-track review, priority approval	Global trials						
Antibiotic Intervention	•Target naturally infected patients with autoimmune symptoms •Antibiotic-based approach for confirmed infection-linked cases •Guidelines Amendments (Pre-Decision) •Multicenter trials (Japan and global), OCT	Specific Clinical Research						
Therapeutic Vaccine	•Desensitization-based approach for naturally infected patients •Preclinical safety studies (animal/human tissue ex vivo) •Vaccine safety studies (GLP/GMP)	Global Multicenter Investigator-Initiated Trials						
Preventive Vaccine	•For high-risk population (e.g., interstitial pneumonia) •Pre-IND consultation •Pre-IND dose escalation trial	Investigator-Initiated / Corporate Clinical Trials						

REVENUE MODEL

Accelerating Market Access via FDA BDD/BTD Pathways

COMPETITIVE ADVANTAGE

- Unique focus on infection-triggered autoimmunity
- Integrated platform: diagnostics + therapeutics + digital support

EXIT

- Partnering with major pharmaceutical companies accelerates global expansion of preventive vaccines
- Contract lump sum + development, approval, and sales milestones + royalties as return
- Social infrastructure for AI medical infectious diseases